Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients — Stella

Home/Chronic Kidney Diseases/Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

View on ClinicalTrials.gov

Recruiting

Back to Chronic Kidney Diseases trials

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(2 sites)

United States

University of Texas at Arlington, Arlington, Texas

UT Southwestern, Dallas, Texas

Key details

Phase

Post-approval study

Sponsor

The University of Texas at Arlington

Collaborators

University of Texas, Southwestern Medical Center at Dallas

Enrollment target

~28 participants

Started

April 2018

Primary completion

April 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

35 Years – 70 Years

Last updated June 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.